ユタにおける膀胱癌の臨床試験
ユタ内の拠点で、膀胱癌に関する14件の研究が参加者を募集しています。
ユタ内の都市
公式研究テキスト（英語）
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07061964Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Huntsman Cancer Institute - University of Utah, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Mountain Region, LLC, West Valley City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06465069KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
- Huntsman Cancer Institute ( Site 5041), Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07232602FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Utah, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/07更新 · NCT04752722Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Intermountain Medical Center, Murray
- St George Regional Hospital Cancer Center, St. George
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/29更新 · NCT07106762Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257Improving Care for Rural Patients With Solid Tumors
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
被験者募集中
18歳〜99歳 · 全性別 · 2026/02/05更新 · NCT04916990SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。